Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113830
Chunk: 2

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 2
---
Selling Stockholders”), from time to time, of an aggregate of 37,911,081 shares of common stock, par value $0.01 per share (the “Common Stock”) of Heron Therapeutics, Inc. (the “Company,” “we” or “us”), consisting of (i) 13,225,227 shares of Common Stock issued to certain purchasers pursuant to a securities purchase agreement with the Company dated August 8, 2025 (the “Purchase Agreement”), (ii) an aggregate of 5,241,410 shares of Common Stock issuable upon automatic conversion of the Company’s Series A convertible preferred stock, par value $0.01 per share (the “Series A Convertible Preferred Stock”), subject to Stockholder Approval (as defined below) issued to certain purchasers pursuant to the Purchase Agreement and (iii) an aggregate of 19,444,444 shares of Common Stock issuable upon the conversion, at the option of the holder, of convertible senior unsecured promissory notes due 2031 (the “Notes”), subject to Stockholder Approval, issued to a fund affiliated with Rubric Capital Management LP (“Rubric”) pursuant to the note purchase agreement with the Company dated August 8, 2025 (“the Note Purchase Agreement”).

We are not selling any shares of Common Stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of Common Stock by the Selling Stockholders.

The Selling Stockholders or their pledgees, assignees, permitted transferees or other successors-in-interest may offer and sell or otherwise dispose of the shares of Common Stock described in this prospectus from time to time through public or private transactions at fixed prices, at prevailing market prices, at prices related to prevailing market prices, at varying prices determined at time of sale, or at privately negotiated prices. The Selling Stockholders will bear all commissions and discounts, if any, attributable to the sales of shares. We will bear all costs, expenses and fees in connection with the registration of the shares. See “Plan of Distribution” beginning on page 19 for more information about how the Selling Stockholders may sell or dispose of their shares of Common Stock.

Our Common Stock is listed on The Nasdaq Capital Market under the symbol “HRTX.” On September 3, 2025, the last reported sale price of our Common Stock was $1.33 per share.

Investing in our securities involves risk. See “Risk Factors” beginning on page 15 of